Laboratory of Nucleic Acid Vaccines, Department of Medicine
Immunology of Infectious Disease | Immunoprophylaxis and Therapy | Immunotherapy | Infectious Disease | Microbiology | Virus Diseases
The rapidly emerging SARS-2-CoV (SARS-2) has been spreading through China and entering many parts of the world with easy human-to-human transmission and thousands of deaths. Development of a vaccine, and a vaccine which can be quickly deployed on a global scale, is no longer merely a discussion or part of a debate whether such a vaccine is ultimately needed.
SARS-2-CoV, SARS-2, vaccines, vaccination, 2019-nCoV, COVID-19
Rights and Permissions
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor and Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI of Published Version
Emerg Microbes Infect. 2020 Dec;9(1):542-544. doi: 10.1080/22221751.2020.1737580. Link to article on publisher's site
Emerging microbes and infections
Lu S. (2020). Timely development of vaccines against SARS-CoV-2. Coronavirus COVID-19 Publications by UMMS Authors. https://doi.org/10.1080/22221751.2020.1737580. Retrieved from https://escholarship.umassmed.edu/covid19/1
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.